Unless the data is impeccable, Leronlimab isn’t getting approved based on an interm dataset. And based on the EIND data already shared, it will not be impeccable.
Remember Phase 3 actemra data is going be available in the same timeframe. It’s pretty clear to me FDA will want phase 3 data from Leronlimab.